A Plus Biotechnology Co., Ltd. (TPE:6918)
80.90
-0.20 (-0.25%)
At close: Jan 20, 2026
A Plus Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 171.54 | 151.06 | -11.31 | 32.94 | 36.06 |
Depreciation & Amortization | 24.49 | 24.56 | 23.39 | 21.43 | 25.48 |
Other Amortization | 2.19 | 2.14 | 2.99 | - | - |
Loss (Gain) From Sale of Assets | 0 | 0.01 | - | - | 0 |
Asset Writedown & Restructuring Costs | - | - | 164.46 | - | - |
Stock-Based Compensation | 0.55 | 1.2 | - | 1.71 | - |
Provision & Write-off of Bad Debts | - | -0.18 | 0.17 | -0.6 | -7.68 |
Other Operating Activities | 27.47 | 4.16 | -18.4 | 38.25 | 37.85 |
Change in Accounts Receivable | -10.03 | -36.71 | 2.83 | -2.94 | -22.25 |
Change in Inventory | -60.11 | -3.82 | 9.27 | -55.36 | 32.45 |
Change in Accounts Payable | 22.05 | 10.59 | -10.48 | 15.8 | -3.53 |
Change in Unearned Revenue | 2.76 | -0.62 | -5.22 | -1.66 | -0.99 |
Change in Other Net Operating Assets | -21.64 | 8.56 | 1.4 | 3.38 | 14.81 |
Operating Cash Flow | 157.3 | 160.96 | 159.1 | 52.95 | 112.21 |
Operating Cash Flow Growth | -12.32% | 1.16% | 200.47% | -52.81% | - |
Capital Expenditures | -11.91 | -8.87 | -9.38 | -221.5 | -4.86 |
Sale (Purchase) of Intangibles | -0.51 | -0.27 | -0.43 | -3.41 | -0.8 |
Investment in Securities | -185 | -30 | - | - | 141.45 |
Other Investing Activities | -3.73 | 0.09 | 4.96 | -9.32 | 1.41 |
Investing Cash Flow | -201.44 | -39.05 | -4.85 | -234.23 | 137.19 |
Short-Term Debt Issued | - | - | - | 5.87 | - |
Long-Term Debt Issued | - | - | - | 165 | - |
Total Debt Issued | - | - | - | 170.87 | - |
Short-Term Debt Repaid | - | - | - | - | -50.28 |
Long-Term Debt Repaid | - | -16.32 | -35.17 | -12.97 | -9.73 |
Total Debt Repaid | -13.81 | -16.32 | -35.17 | -12.97 | -60.01 |
Net Debt Issued (Repaid) | -13.81 | -16.32 | -35.17 | 157.9 | -60.01 |
Issuance of Common Stock | 333.02 | 30.32 | - | 54.66 | - |
Repurchase of Common Stock | - | -16.25 | -14.15 | - | - |
Common Dividends Paid | -121.88 | -81.49 | -21.13 | -14.32 | - |
Other Financing Activities | -2.3 | 3.26 | 1.27 | -1.08 | 2.23 |
Financing Cash Flow | 195.03 | -80.49 | -69.18 | 197.16 | -57.78 |
Foreign Exchange Rate Adjustments | -3.58 | 0.48 | -3.7 | -0.09 | -2.69 |
Net Cash Flow | 147.3 | 41.9 | 81.38 | 15.78 | 188.94 |
Free Cash Flow | 145.39 | 152.09 | 149.72 | -168.55 | 107.35 |
Free Cash Flow Growth | -14.70% | 1.58% | - | - | - |
Free Cash Flow Margin | 17.61% | 19.76% | 22.18% | -31.11% | 21.33% |
Free Cash Flow Per Share | 4.56 | 5.01 | 4.95 | -5.83 | 3.75 |
Cash Interest Paid | 3.17 | 3.19 | 2.69 | 2.18 | 1.16 |
Cash Income Tax Paid | 14.1 | 33.14 | 32.76 | 5.85 | 6.1 |
Levered Free Cash Flow | 112 | 97.17 | - | -169.04 | - |
Unlevered Free Cash Flow | 113.35 | 98.54 | - | -167.67 | - |
Change in Working Capital | -66.97 | -22 | -2.2 | -40.79 | 20.5 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.